MTOR and acute promyelocytic leukemia: Of note, rapamycin, the inhibitor of mTOR pathway, synergizes with ATO in the eradication of leukemia-initiating cells (LIC) through the activation of NETosis in both APL cells and an in vivo APL model [129].